MOLECULAR APPROACHES FOR DEVELOPMENT OF AN HIV VACCINE--RHESUS MACAQUES MODEL

HIV疫苗开发的分子方法——恒河猴模型

• 批准号: 3838470
• 负责人: G FRANCHINI
• 金额: --
• 依托单位: DIVISION OF CANCER EPIDEMIOLOGY AND GENETICS
• 依托单位国家: 美国
• 资助国家: 美国
• 起止时间: 至
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/3838470
• 关键词: AIDS vaccines; HIV infections; Macaca mulatta; Salmonella typhimurium; active immunization; attenuated microorganism; bacterial vaccines; disease /disorder model; drug delivery systems; drug screening /evaluation; human immunodeficiency virus 1; human immunodeficiency virus 2; human tissue; immunogenetics; live vaccine; nonhuman therapy evaluation; simian immunodeficiency virus; vaccinia virus; virus antigen

This project is a continuation from last year. Its aim is to test in rhesus macaques the efficacy of various live vectors carrying human immunodeficiency virus type-1 (HIV-1), HIV-2 and simian immunodeficiency virus (SIV) antigens in eliciting a protective immunoresponse. We are testing three different delivery systems: 1) attenuated vaccinia and avipox carrying HIV and SIV antigens; and 2) attenuated Salmonella typhimurium strain as a bacterial vaccine, carrying HIV/SIV antigens. We are also planning to further stimulate the immunoresponse in the immunized animals using purified viral antigens (either native or recombinant viral subunits). We will use rhesus macaques which are susceptible to the infection of both SIV(mac251) and HIV-2(SBL/ISY). The end point of our studies will be the protection from infection by either SIV or HIV-2. Vectors containing HIV-1 antigens will also be evaluated for their immunogenicity in rhesus macaques. The immune animals will be challenged in the next few months.

这个项目是去年的延续。 其目的是测试在 恒河猴的功效，各种活载体携带人类 免疫缺陷病毒1型（HIV-1）、HIV-2和猿猴免疫缺陷 病毒（SIV）抗原引发保护性免疫反应。 我们 测试三种不同的递送系统：1）减毒牛痘， 携带HIV和SIV抗原的禽痘;和2）减毒沙门氏菌 作为细菌疫苗的鼠伤寒菌株，携带HIV/SIV抗原。 我们 还计划进一步刺激免疫反应， 使用纯化的病毒抗原（天然或 重组病毒亚单位）。 我们将使用恒河猴， 对SIV（mac 251）和HIV-2（SBL/ISY）都敏感。 的 我们研究的终点将是保护免受感染， SIV或HIV-2。 还将评价含有HIV-1抗原的载体 在恒河猴中的免疫原性。 免疫的动物会 在接下来的几个月里受到挑战。